University of California- San Francisco

OptiKira, a New Biotech Start-up, Created to Develop Drugs to Prevent Cell Death Caused by the Unfolded Protein Response

BioMotiv, a drug development accelerator associated with The Harrington Project, the University of California, San Francisco (UCSF), and University of Washington, Seattle, are announcing the formation of OptiKira, a platform company that will develop small molecule therapeutics that prevent cell death in pathologies caused by misfolded or unfolded proteins.